Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20
- Stem cells
- cell therapy
- Drug Discovery
- Packaging & Containers
- bone marrow
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 297144
Mesenchymal stem cells is for the medical research and biotech community that offers large volumes of high-quality, low passage human umbilical cord mesenchymal stem cells with minimal batch-to-batch variability.
IPSCIO Record ID: 246210
License is for the methodology for producing clinical-grade pooled human umbilical cord derived mesenchymal stem/stromal cells (â€œHucMSCâ€) at industrial scale.
IPSCIO Record ID: 340079
The transwell migration assay is a commonly used test to study the migratory response of endothelial cells to angiogenic inducers or inhibitors. This assay is also known as the Boyden or modified Boyden chamber assay.
IPSCIO Record ID: 273421
With this amendment, The University Regents grant a world-wide license under The Universitys undivided interest in Patent Rights to make, have made, use, sell, offer to sell and import Product and to practice Licensed Method in the Field.
The patents include Isolation of Stromal Cells from Adipose Tissue, Isolation of Mesenchymal Stem Cells from Adipose Tissue, and, Adipose-Derived Stem Cells and Lattices.
Product means Research Product and Clinical Product.
Licensee is commercializing an automated device called Celution, which when operated in conjunction with various disposable component parts is capable of producing a heterogeneous isolate of the material naturally occurring in adipose tissue including unmodified amounts of stem cells and other regenerative cells, intended for human therapeutic, diagnostic, cosmetic and other uses.
The patented CelutionÂ® family of products process patientsâ€™ adipose-derived stem and regenerative cells (ADRCs) at the point of care. The CelutionÂ® family of products consists of a central device, a related single-use consumable used for each patient procedure, proprietary enzymes, and related instrumentation. Licensee commercialization model is based on the sale of CelutionÂ® Systems and on generating recurring revenues from the single-use consumable sets.
Commercial activities are currently focused on cosmetic and reconstructive surgery in Europe and Asia-Pacific, where Cytoriâ€™s core product, the CelutionÂ® System, provides physicians with clinical grade stem and regenerative cells.
IPSCIO Record ID: 345978
IPSCIO Record ID: 47933
PCX006 is a patent family claiming a non osteochondral derived multipotent adult stem cell population characterized by a set of biological markers.
PCX007 is a patent family claiming an adipose derived stem cell composition characterized by a panel of cell surface markers, methods of preparation of such a composition and adipose tissue derived stromal stem cells in treating fistula and wounds.
(WO2006037649/11/167,061) IDENTIFICATION AND INSOLATION OF MULTIPOTENT CELLS FROM NON-OSTEOCHONDRAL MESENCHYMAL TISSUE
The present invention relates to isolated multipotent adult cells which are isolated from non-osteochondral mesenchymal tissue and are characterized by the presence and absence of a set of cell surface markers. The invention also relates to a method for identifying and isolating a population of said cells, as well as to the applications thereof, for example, in the manufacture of a pharmaceutical composition for the repair and regeneration of tissues.
IPSCIO Record ID: 382728
Licensor has the unique strength of combining stem cell research focused on different organs and developmental stages with leading expertise in cellular plasticity, epigenetics and disease models. This unique combination has led to breakthrough discoveries at the crossroads between disease models and repair, cellular plasticity and disease as well as reprogramming.
IPSCIO Record ID: 383557
MSC shall mean human cells that are capable of differentiation into more than one mesenchymal lineage.
Product means any product or composition that contains MSC and/or any process or service performed with respect to recovery, expansion, maintenance, purification, storage, production, formulation or use of MSC.
The patents include
— Monoclonal antibodies specific for marrow-derived mesenchymal cells;
— Uses for non-autologus mesenchymal stem cells;
— Osteoporosis bond regeneration;
— Mesenchymal stem cells for prevention and treatment of immune responses in transplantation;
— Mesenchymal stem cells as immunosuppressants;
— Regulation of Hema topoietic stem cell differentiation by the use of human mesenchymal stem cells;
— Uses of fibroblasts or supernatants from fibroblasts for the suppression of immune responses in transplantation.
Hematologic malignancies are cancers that begin in blood-forming tissue, such as the bone marrow, or in the cells of the immune system. There are three main types of hematologic malignancies leukemia, lymphoma and multiple myeloma.
IPSCIO Record ID: 383612
Chondrogen shall mean any formulation, dosage form or delivery system that contains culturally expanded, undifferentiated, unmodified human MSCs for local delivery for the Articulating Orthopedic Indication and any Improvements thereto.
Prochymal shall mean any formulation, dosage form or delivery system suitable for Vascular Administration that contains culturally expanded, undifferentiated, unmodified human MSCs, and any Improvements thereto.
Ulcerative Colitis Indication shall mean the use of Prochymal for the treatment or prevention of ulcerative colitis.
Mesenchymal Stem Cells or MSCs shall mean the human formative pluripotential blast cells found inter alia in bone marrow, blood, dermis and periosteum that are capable of differentiating into any of the specific types of mesenchymal or connective tissues.
COPD Indication shall mean the use of Prochymal to treat chronic obstructive pulmonary disease.
Articulating Orthopedic Indication shall mean the use of Chondrogen for preventing or treating diseases, defects or conditions of articulating joints, including cartilage and meniscus repair, osteoarthritis, osteochondral defect repair, and the treatment of acute and chronic orthopedic pain within an articulating joint.
Crohns Indication shall mean the use of Prochymal to treat Crohns disease.
Diabetes Indication shall mean the use of Prochymal for the prevention or treatment of Type I diabetes.
GvHD Indication shall mean the use of Prochymal to treat or prevent graft versus host disease.
Cardiac Indication shall mean the use of Prochymal to treat or prevent acute myocardial infarction.
Pain Therapeutic shall mean use of Chondrogen for the mitigation or relief of orthopedic pain with a Statistically Significant duration of relief of at least one year.
IPSCIO Record ID: 204653
IPSCIO Record ID: 47833
IPSCIO Record ID: 307629
The University grants an exclusive option to obtain
(a) an exclusive worldwide license under Patent Rights B to make, have made, use, import, offer for sale, sell and otherwise commercially exploit Licensed Products and to practice Licensed Processes, and the exclusive right to use regulatory data and technical information in connection with such licensed patent rights, in the Field of use and Territory; and
(b) an exclusive license under Patent Rights A to make, have made, use, import, offer for sale, sell and otherwise commercially exploit Licensed Products and to practice Licensed Processes, and the exclusive right to use Regulatory Data and Technical Information in connection with such licensed patent rights, in the Field of Use and Territory except for the Excluded fields of uses in the Excluded Territory.
Patent Rights Group (A) include
METHODS OF TREATING BRAIN INJURY USING CORD BLOOD OR A COMPONENT THEREOF,
COMPOSITIONS AND METHODS OF THE TREATMENT OF DEMYLINATING CONDITIONS,
METHODS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDERS,
Patent Rights Group (B) include
METHODS OF TREATING CEREBRAL PALSY USING HIGH DOSE ALLOGENEIC UMBILICAL CORD BLOOD,
METHODS OF TREATING CEREBRAL PALSY AND HYPOXIC-ISCHEMIC ENCEPHALOPATHY USING HUMAN UMBILICAL CORD TISSUE-DERIVED MESENCHYMAL STROMAL CELLS,
METHODS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDERS USING HUMAN UMBILICAL CORD TISSUE-DERIVED MESENCHYMAL STROMAL CELLS,
â€¢ COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEMYELINATING CONDITIONS
COMPOSITIONS COMPRISING MESESCHYMAL STROMAL CELLS FOR THE TREATMENT OF VIRAL INFECTIONS
Option agreement brings novel cord blood and birthing tissue based cellular therapeutics to the clinic.
The company services include the cryopreservation of umbilical cord blood and cord tissue. The company has also patented a method for processing endometrial stem cells from menstrual blood.
IPSCIO Record ID: 4928
Method of Isolation of Stem Cells and Bag Array U.S. #08/349,747
Improved Bag Design and Method of Manufacturing U.S. #08/670,368
Non-Exclusive Field of Use@ shall mean all other applications of the Licensed Product.
IPSCIO Record ID: 6088
a. 'Collection' or 'Collected' means accumulation of or accumulated Cord Blood in a container.
b. 'Cord Blood' means blood or any blood components (including without limitation stem cells) collected from a human umbilical cord and/or placenta.
c. 'Cryopreservative' means an agent capable of preserving at very low temperatures.
d. 'Cryopreserve' means to preserve a material, such as Cord Blood or Stem Cells, by freezing.
e. 'Cryopreserved Blood' means (i) frozen Cord Blood, (ii) frozen and thawed Cord Blood or (iii) any other composition which would, but for this Agreement, infringe one or more claims of the Licensed Patents, in all three instances with or without a Cryopreservative.
g. 'Expanded Stem Cells' means Stem Cells, expanded from Cryopreserved Blood, or Cryopreserved after expansion.
i. 'Licensed Patents' means U.S. Patents Nos. 5,004,681, 5,192,553, 6,461,645, 6,569,427 and 6,605,275 and all patents that are related to any or all of those patents through priority or otherwise, directly or indirectly, including but not limited to, continuations, continuations in part, divisions, reissues and reexaminations thereof, and shall further include any other.
j. 'Licensed Process' means any process for the Collection, storage or use of Cord Blood that would, but for this Agreement, infringe one or more claims of Licensed Patents.
k. 'Modified Stem Cells' means Stem Cells, modified from Cryopreserved Blood, or Cryopreserved after modification.
IPSCIO Record ID: 3056
IPSCIO Record ID: 336338
Licensor is the co-owner with a Hospital Corporation of certain Patent Rights. The patents are Method to Modulate Hematopoietic Stem Cell Growth, and, Method to Enhance Tissue Regeneration.
ZON IND shall mean the investigational new drug application titled A Phase I Study of Reduced Intensity, Sequential Double Umbilical Cord Blood Transplantation Using Ex-Vivo 16,16 Dimethyl-Prostaglandin E2 Expanded Umbilical Cord Blood Units.
Licensee's lead product candidate, ProHema, is a pharmacologically modulated HSC therapeutic derived from umbilical cord blood. Licensee has established human proof-of-concept for ProHema in the clinical setting by demonstrating enhanced and durable engraftment of HSCs within the bone marrow. Engraftment, which is the localization and integration of HSCs within a targeted tissue where they can produce new cells, is an important determinant of patient outcomes in HSCT. Licensee is presently advancing ProHema in Phase 2 clinical development for hematologic malignancies. Licensee is also pursuing the development of pharmacologically optimized HSC therapeutics for the treatment of certain lysosomal storage disorders, or LSDs, where HSCs have demonstrated the ability to home, or migrate, to and engraft within the central nervous system, or CNS.
IPSCIO Record ID: 279305
Licensor grants a non-exclusive, non-transferable license, without the right to grant or authorize sublicenses except as expressly set forth, under the Licensed Patents to make, have made, use, develop, sell, offer to sell, and distribute the Licensed Differentiated Cell Products and Licensed Services in the Field and in the Territory.
Licensed Pluripotent Cell Products means any induced pluripotent stem cell or induced pluripotent stem cell line produced by methods covered by the Licensed Patents.
Licensed Products means both Licensed Differentiated Cell Products and Licensed Pluripotent Cell Products including Cardiomyocytes, Hematopoeitic cells, Neural cells, Hepatocytes, Endothelial cells, Bone cells, Cartilage, Pancreatic cells, Fat cells and Lung cells.
The iPSC technology was pioneered Japan, who showed in 2006 that the introduction of four specific genes encoding transcription factors could convert adult cells into pluripotent stem cells.
Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells.
Pluripotent stem cells hold promise in the field of regenerative medicine. Because they can propagate indefinitely, as well as give rise to every other cell type in the body (such as neurons, heart, pancreatic, and liver cells), they represent a single source of cells that could be used to replace those lost to damage or disease.
IPSCIO Record ID: 26528
IPSCIO Record ID: 7349
Certain biological materials and reagents (including master and working cell banks, original and seed banks, and research, pilot and GMP grade lots and finished product);
Certain regulatory filings for clinical trials for GRNOPC-I for spinal cord injury, including the investigational new drug applications filed with the United States Food and Drug Administration for Licensorâ€™s Phase I safety study of oligodendrocyte progenitor (GRNOPC-1) cells in patients with neurologically complete, subacute spinal cord injury (Protocol No. CP35A007), and long term follow up of subjects who received GRNOPC1 (Protocol No. CP35A008), and the clinical trial for VAC1 for acute myelogenous leukemia, including a Phase I/II study of active immunotherapy with GRNVAC1, autologous mature dendritic cells transfected with mRNA encoding human telomerase reverse transcriptase (hTERT), in patients with acute myelogenous leukemia (AML) in complete remission (Protocol No. CP06-151).
US Patent 6,800,480 – Methods and Materials for the Growth of Primate-Derived Primordial Stem Cells in Feeder-Free Culture
US Patent 7,413,902 – Feeder-Free Culture Method for Embryonic Stem Cells
US Patent 6,440,735 – Dendritic Cell Vaccine Containing Telomerase Reverse Transcriptase for the Treatment of Cancer
US Patent 7,402,307 – Method for Identifying and Killing Cancer Cells
US Patent 7,824,849 – Cellular Telomerase Vaccine and Its Use for Treating Cancer
US Patent 7,560,281 – Use of TGF Beta Superfamily Antagonists to Make Dopaminergic Neurons from Embryonic Stem Cells
US Patent 8,252,586 – Neural Cell Populations from Primate Pluripotent Stem Cells
US Patent 8,153,428 – Use of TGF Beta Superfamily Antagonists and Neurotrophins to Make Neurons from Embryonic Stem Cells
US Patent 6,667,176 – cDNA Libraries Reflecting Gene Expression During Growth and Differentiation of Human Pluripotent Stem Cells
US Patent 7,041,438 – Use of Human Embryonic Stem Cells for Drug Screening and Toxicity Testing
US Patent 7,413,904 – Embryonic Stem Cells Having Genetic Modifications
US Patent 7,410,798 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent 7,297,539 – Medium for Growing Human Embryonic Stem Cells
US Patent 7,455,983 – Medium for Growing Human Embryonic Stem Cells
US Patent 8,097,458 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent 6,642,048 – Conditioned Media for Propagating Human Pluripotent Stem Cells
US Patent 6,458,589 – Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
US Patent 6,506,574 – Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
US Patent 7,256,042 – Process for Making Hepatocytes from Pluripotent Stem Cells
US Patent 7,282,366 – Hepatocytes for Therapy and Drug Screening Made From Embryonic Stem Cells
US Patent 7,473,555 – Protocols for Making Hepatocytes from Embryonic Stem Cells
US Patent 8,148,151 – Differentiation of Primate Pluripotent Cells to Hepatocyte-Lineage Cells
US Patent 6,833,269 – Making Neural Cells for Human Therapy or Drug Screening from Human Embryonic Stem Cells
US Patent 8,148,148 – Neural Progenitor Cell Populations
US Patent 8,252,585 – Neural Progenitor Cell Populations
US Patent 7,250,294 – Screening Small Molecule Drugs Using Neural Cells Differentiated from Human Embryonic Stem Cells
US Patent 7,763,463 – Use of Cyclic AMP and Ascorbic Acid to Produce Dopaminergic Neurons from Embryonic Stem Cells
US Patent 6,576,464 – Differentiated Cells Suitable For Human Therapy
US Patent 6,921,665 – Selective Antibody Targeting of Undifferentiated Stem Cells
US Patent 7,732,199 – Process for Making Transplantable Cardiomyocytes from Human Embryonic Stem Cells
US Patent 7,763,464 – Differentiation Protocol for Making Human Cardiomyocytes
US Patent 7,452,718 – Direct Differentiation Method for Making Cardiomyocytes from Human Embryonic Stem Cells
US Patent 7,897,389 – Direct Differentiation Method for Making Cardiomyocytes from Human Embryonic Stem Cells
US Patent 7,851,167 – Differentiation Protocol for Making Human Cardiomyocytes
US Patent Application 13/561,296 – Neural Cell Populations from Primate Pluripotent Stem Cells
US Patent Application 12/170,219 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent Application 12/710,078 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent Application 13/323,567 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent Application 11/917,993 – Suspension Culture of Human Embryonic Stem Cells
US Patent Application 12/277,136 – Protocols for Making Hepatocytes from Embryonic Stem Cells
US Patent Application 13/558,078 – Neural Progenitor Cell Populations
US Patent Application 11/359,341 – Differentiated Cells Suitable For Human Therapy
US Patent Application 11/471,916 – Differentiation of Primate Pluripotent Stem Cells to Cardiomyocyte-Lineage Cells
IPSCIO Record ID: 346226
Aallogeneic hematopoietic stem cell transplantation (allo-HSCT), called Facilitated Allo-HSCT Therapy.
The product candidate, FCR001, which is central to Facilitated Allo-HSCT Therapy, is a novel allogeneic cell therapy comprised of stem and immune cells that are procured from a healthy donor, who is also the organ donor in the case of organ transplantation. FCR001 is rapidly processed in the GMP facility using proprietary manufacturing methods. Then, at the time of the transplant, FCR001 is administered to the recipient following nonmyeloablative conditioning, which is designed to be less toxic than myeloablative conditioning. A fully myeloablative conditioning regimen consists of a combination of agents and high doses of total body irradiation that destroy hematopoietic stem cells (HSCs) in the bone marrow and results in profound depletion of HSC-derived cells within one to three weeks following administration that is irreversible, and in most instances is fatal unless rescued by a stem cell transplant. The nonmyeloablative conditioning for FCR001 entails lower doses of chemotherapy and total body irradiation, causes less depletion of blood cells and does not require stem cell support for the recipient to resume the production of blood cells and platelets.
Allo-HSCT Therapy has the potential to treat a range of severe autoimmune diseases and severe non-malignant blood, immune and metabolic disorders, in each case with potential for similar outcomes to what has previously been observed with HSCT, while mitigating the toxicities, morbidities and extended hospital stay associated with the conditioning regimen typically required by HSCT.
Facilitated Allo-HSCT Therapy could prevent organ rejection without the morbidity and mortality that has been associated with the use of lifelong anti-rejection medicines, also known as chronic immunosuppression.